| 000 | 01843 a2200553 4500 | ||
|---|---|---|---|
| 005 | 20250517054749.0 | ||
| 264 | 0 | _c20161005 | |
| 008 | 201610s 0 0 eng d | ||
| 022 | _a1460-2091 | ||
| 024 | 7 |
_a10.1093/jac/dkv300 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aGerding, D N | |
| 245 | 0 | 0 |
_aSusceptibility of Clostridium difficile isolates from a Phase 2 clinical trial of cadazolid and vancomycin in C. difficile infection. _h[electronic resource] |
| 260 |
_bThe Journal of antimicrobial chemotherapy _cJan 2016 |
||
| 300 |
_a213-9 p. _bdigital |
||
| 500 | _aPublication Type: Clinical Trial, Phase II; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 | _aAdolescent |
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 | _aAged, 80 and over |
| 650 | 0 | 4 |
_aAnti-Bacterial Agents _xadministration & dosage |
| 650 | 0 | 4 |
_aClostridioides difficile _xclassification |
| 650 | 0 | 4 |
_aClostridium Infections _xdrug therapy |
| 650 | 0 | 4 | _aDouble-Blind Method |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMicrobial Sensitivity Tests |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 |
_aOxazolidinones _xadministration & dosage |
| 650 | 0 | 4 | _aRibotyping |
| 650 | 0 | 4 |
_aVancomycin _xadministration & dosage |
| 650 | 0 | 4 | _aYoung Adult |
| 700 | 1 | _aHecht, D W | |
| 700 | 1 | _aLouie, T | |
| 700 | 1 | _aNord, C E | |
| 700 | 1 | _aTalbot, G H | |
| 700 | 1 | _aCornely, O A | |
| 700 | 1 | _aBuitrago, M | |
| 700 | 1 | _aBest, E | |
| 700 | 1 | _aSambol, S | |
| 700 | 1 | _aOsmolski, J R | |
| 700 | 1 | _aKracker, H | |
| 700 | 1 | _aLocher, H H | |
| 700 | 1 | _aCharef, P | |
| 700 | 1 | _aWilcox, M | |
| 773 | 0 |
_tThe Journal of antimicrobial chemotherapy _gvol. 71 _gno. 1 _gp. 213-9 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1093/jac/dkv300 _zAvailable from publisher's website |
| 999 |
_c25322069 _d25322069 |
||